Group One Trading
CADX

Group One Trading’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Group One Trading’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-33,200
Closed -$300K – 5997
2013
Q4 		$300K Buy
33,200
+29,500
+797% +$213K ﹤0.01% 2075
2013
Q3 		$23K Buy
3,700
+300
+9% +$1.91K ﹤0.01% 4108
2013
Q2 		$23K Buy
+3,400
New +$23.7K ﹤0.01% 4007

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Group One Trading's CADX Position: Q4 2013 in Review

Group One Trading sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 6,188 shares — an estimated $44.7K sold.

Group One Trading first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $39K in Q3 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

  • Group One Trading reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
  • Group One Trading sold 6,188 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $44.7K.
  • Group One Trading first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
  • Group One Trading's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $39K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on Group One Trading's 13F filing for Q4 2013, filed 31 Jan 2014.